KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Short-term Investments: 2020-2025

Historic Short-term Investments for CRISPR Therapeutics AG (CRSP) over the last 5 years, with Sep 2025 value amounting to $1.6 billion.

  • CRISPR Therapeutics AG's Short-term Investments fell 4.72% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 4.72%. This contributed to the annual value of $1.6 billion for FY2024, which is 23.11% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Short-term Investments of $1.6 billion as of Q3 2025, which was up 6.65% from $1.5 billion recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Short-term Investments high stood at $1.7 billion for Q3 2024, and its period low was $680.1 million during Q1 2021.
  • Moreover, its 3-year median value for Short-term Investments was $1.5 billion (2025), whereas its average is $1.5 billion.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Short-term Investments spiked by 351.61% in 2021 and then decreased by 18.66% in 2023.
  • Quarterly analysis of 5 years shows CRISPR Therapeutics AG's Short-term Investments stood at $1.5 billion in 2021, then grew by 10.12% to $1.6 billion in 2022, then fell by 18.66% to $1.3 billion in 2023, then climbed by 23.11% to $1.6 billion in 2024, then declined by 4.72% to $1.6 billion in 2025.
  • Its Short-term Investments was $1.6 billion in Q3 2025, compared to $1.5 billion in Q2 2025 and $1.6 billion in Q1 2025.